Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Content from other channels on our network

Australia–Japan laser a new step towards advanced defence manufacturing

Robots have a positive effect on employment and productivity: report

Hazer technology to be evaluated by major Japanese power utility

Researchers recover silver from end‍-‍of‍-‍life solar panels

Muting in practice: when safety becomes a vulnerability

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point

Commonwealth Home Support Program extended to 30 June 2029

When Connectivity Becomes Critical Care — Webinar

Unregistered doctor convicted after patient is hospitalised following medical procedure

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

Smart stormwater system removes harmful pollutants

Researchers create compact supercapacitor designed for reuse

ARRC Gold Coast calls for market certainty on plastics